Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

GlaxoSmithKline Pharma Ltd announced its Q3 results today posting a solid jump in its net profit. Consolidated PAT for the ...

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, ...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

Kingsview Wealth Management LLC lowered its holdings in GSK plc (NYSE:GSK – Free Report) by 11.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

GSK Pharma reported strong Q3 performance with revenue up 18% and EBITDA rising 34%. Key brands, including Augmentin and ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...